Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, et al. Blood 2023 Mar 10:blood.2022019160. doi: 10.1182/blood.2022019160.

Read + Share

Amedeo Smart

Independent Medical Education

Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, et al. Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood 2023 Mar 10:blood.2022019160. doi: 10.1182/blood.2022019160.
PMID: 36898087